EFFECT OF THE TGFΒ1 Arg25Pro POLYMORPHISM ON TREATMENT EFFICACY AND CLINICAL-FUNCTIONAL PARAMETERS IN CHRONIC HEART FAILURE
Abstract
Chronic heart failure (CHF) is one of the common and severe complications of ischemic heart disease (IHD), in the development of which myocardial remodeling and fibrotic processes play an important role [1–2]. The TGFβ1 gene is involved in the molecular regulation of these processes. Therefore, investigation of the TGFβ1 Arg25Pro (rs1800471) polymorphism is relevant to the genetic assessment and prediction of the risk of CHF in patients with IHD [5].
Downloads
References
1. Packer M., Anker S.D., Butler J., Filippatos G., Pocock S.J., Carson P., et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. New England Journal of Medicine. 2020;383: 1413–1424.
2. Anker S.D., Butler J., Filippatos G., Ferreira J.P., Bocchi E., Böhm M., et al. Empagliflozin in heart failure with a preserved ejection fraction. New England Journal of Medicine. 2021;385(16):1451–1461.
3. Packer M., Anker S.D., Butler J., Filippatos G., Pocock S.J., Ferreira J.P., et al. Empagliflozin in patients with heart failure, reduced ejection fraction, and volume overload: EMPEROR-Reduced Trial. Journal of the American College of Cardiology. 2021;77(11):1381–1392.
4. Butler J., Filippatos G., Siddiqi T.J., et al. Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved Trial. Circulation. 2021;145(3):184–193.
5. Packer M., Anker S.D., Butler J., Filippatos G., Pocock S.J., Carson P., et al. Effect of empagliflozin on worsening heart failure events in patients with heart
